OPTN (Option Therapeutics) Current Accrued Expense: $0.01 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Option Therapeutics Current Accrued Expense?

Option Therapeutics OPTN Current Accrued Expense is $0.01 Mil as of Dec. 2025.

Option Therapeutics's Current Accrued Expense for the quarter that ended in Dec. 2025 was $0.01 Mil.

Option Therapeutics's quarterly Current Accrued Expense declined from Jun. 2025 ($0.13 Mil) to Sep. 2025 ($0.02 Mil) and declined from Sep. 2025 ($0.02 Mil) to Dec. 2025 ($0.01 Mil).

Option Therapeutics's annual Current Accrued Expense increased from . 20 ($0.00 Mil) to Jun. 2024 ($0.01 Mil) and increased from Jun. 2024 ($0.01 Mil) to Jun. 2025 ($0.13 Mil).

Option Therapeutics Current Accrued Expense Related Terms

Option Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Option Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Option Therapeutics Current Accrued Expense Chart

Option Therapeutics Annual Data
Trend Jun24 Jun25
Current Accrued Expense
0.01 0.13

Option Therapeutics Quarterly Data
Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Current Accrued Expense Get a 7-Day Free Trial 0.00 0.00 0.13 0.02 0.01

Option Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.01 Mil mean?
Option Therapeutics (OPTN) has a Current Accrued Expense of $0.01 Mil as of Dec. 2025. Current Accrued Expense records the total amount of accrued expenses. View historical data on Option Therapeutics and its competitors.
Is Option Therapeutics' Current Accrued Expense too high?
Option Therapeutics' current Current Accrued Expense is $0.01 Mil.
How does Option Therapeutics' Current Accrued Expense compare to ?
Option Therapeutics' Current Accrued Expense of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Option Therapeutics and its competitors. Option Therapeutics's current Current Accrued Expense is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Option Therapeutics stock overvalued right now?
Option Therapeutics (OPTN) has a current Current Accrued Expense of $0.01 Mil. The current Current Accrued Expense is $0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Option Therapeutics (OPTN), the current Current Accrued Expense is $0.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Option Therapeutics Business Description

Comparable Companies
Address 680 West Nye Lane, Suite 201, Carson, NV, USA, 89703
Option Therapeutics Inc is a clinical-stage company developing inventive drug therapies to treat debilitating and life-threatening liver disease through its investigational drug candidate BIV201 (continuous infusion terlipressin). BIV201 is administered as a patent-pending liquid formulation of terlipressin with patents issued, to date, in the U.S., China, Japan, Chile, and India.